Robert K Bright
Overview
Explore the profile of Robert K Bright including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
408
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joshi R, Ahmadi H, Gardner K, Bright R, Wang W, Li W
Lab Chip
. 2025 Jan;
25(5):856-883.
PMID: 39774602
Heterogeneities among tumor cells significantly contribute towards cancer progression and therapeutic inefficiency. Hence, understanding the nature of cancer through liquid biopsies and isolation of circulating tumor cells (CTCs) has gained...
2.
Labib S, Bright R, Liu J
Ultrasound Med Biol
. 2024 Oct;
51(1):1-14.
PMID: 39389856
Ultrasound is well-perceived for its diagnostic application. Meanwhile, ultrasound, especially focused ultrasound (FUS), has also demonstrated therapeutic capabilities, such as thermal tissue ablation, hyperthermia, and mechanical tissue ablation, making it...
3.
Bright R
Hum Vaccin Immunother
. 2023 Oct;
19(3):2273699.
PMID: 37904517
Overexpressed tumor-associated antigens (TAAs) are a large group that includes proteins found at increased levels in tumors compared to healthy cells. Universal tumor expression can be defined as overexpression in...
4.
Washburn R, Martinez-Marin D, Sniegowski T, Korac K, Rodriguez A, Miranda J, et al.
Biomedicines
. 2023 Jun;
11(6).
PMID: 37371745
Transplantation is a clinical procedure that treats a variety of diseases yet is unattainable for many patients due to a nationwide organ shortage and the harsh side effects of chronic...
5.
Elizondo C, Bright J, Bright R
Hum Vaccin Immunother
. 2022 Sep;
18(6):2108656.
PMID: 36069634
Cancer immunotherapy is a powerful tool for inducing antigen-specific antitumor cytotoxic T lymphocytes (CTLs). Next-generation strategies may include vaccination against overexpressed oncogenic tumor-self antigens. Previously, we reported vaccination against the...
6.
Castro-Piedras I, Sharma M, Brelsfoard J, Vartak D, Martinez E, Rivera C, et al.
EMBO Rep
. 2021 Apr;
22(6):e50600.
PMID: 33860601
Dishevelled (DVL) critically regulates Wnt signaling and contributes to a wide spectrum of diseases and is important in normal and pathophysiological settings. However, how it mediates diverse cellular functions remains...
7.
Elizondo C, Bright J, Byrne J, Bright R
Hum Vaccin Immunother
. 2019 Nov;
16(6):1413-1423.
PMID: 31769704
Development of cancer vaccines targeting tumor self-antigens is complex and challenging due to the difficulty of overcoming immune tolerance to self-proteins. Vaccination against tumor self-protein D52 (D52) has been successful,...
8.
Chen Y, Frost S, Khushi M, Cantrill L, Yu H, Arthur J, et al.
Sci Rep
. 2019 Jul;
9(1):9790.
PMID: 31278300
Tumor protein D52 (TPD52) is amplified and overexpressed in breast and prostate cancers which are frequently characterised by dysregulated lipid storage and metabolism. TPD52 expression increases lipid storage in mouse...
9.
Dong Z, Yu D, Liu Q, Ding Z, Lyons V, Bright R, et al.
Nanoscale
. 2018 Aug;
10(35):16795-16804.
PMID: 30160287
Self-floating hollow glass microspheres (HGMS) modified with tumor-specific antibodies have been developed for the capture of circulating tumor cells (CTCs), and have demonstrated effective cell isolation and good viability of...
10.
Kamili A, Roslan N, Frost S, Cantrill L, Wang D, Della-Franca A, et al.
J Cell Sci
. 2015 Jul;
128(17):3223-38.
PMID: 26183179
Tumor protein D52 (TPD52) is amplified and/or overexpressed in cancers of diverse cellular origins. Altered cellular metabolism (including lipogenesis) is a hallmark of cancer development, and protein-protein associations between TPD52...